INS and obesity due to melanocortin 4 receptor deficiency: This evidence primarily comes from real-world data on the use of semaglutide and tirzepatide in T1D patients with concomitant overweight/obesity, although a randomized crossover trial investigating the efficacy of semaglutide in adults with T1D using an automated insulin delivery system has recently been published (discussed later in the manuscript).